Highlights Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Market Closed - Nyse Other stock markets 16:10:00 2024-05-10 EDT			5-day change	1st Jan Change
1.75 ^USD	-2.78%		-3.31%	+335.32%

05-09	Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating	MT
04-30	Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry	04-30	CI
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study	03-18	MT
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma	03-18	CI
Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	02-29	CI
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform	02-01	CI
Perspective Therapeutics, Inc. Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs	01-17	CI
Lantheus Holdings Signs Share Purchase, Licensing Deals With Perspective Therapeutics	01-09	MT
Perspective Therapeutics, Inc. Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability	01-09	CI
Perspective Therapeutics, Inc. entered into an asset purchase agreement to acquire Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. for $8 million.	01-08	CI
Perspective Therapeutics Gains After Licensing Cancer Treatment from Mayo Clinc	01-05	MT
Perspective Therapeutics, Inc. Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment	01-05	CI
Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors	12-07	CI
Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany	11-28	CI
Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals	11-27	CI
Earnings Flash (CATX) PERSPECTIVE THERAPEUTICS Reports Q3 Revenue $2.19M	11-14	MT
Perspective Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors	11-08	CI
Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials	23-10-10	CI
Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine	23-09-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Highlights

Filters